Patient follow-up completed for the 475-patient global Phase 2/3 study of oral opaganib for severe COVID-19
Top-line results expected in the coming weeks
Opaganib, a novel, dual antiviral and anti-inflammatory investigational COVID-19 pill, demonstrated potent inhibition of Beta and Gamma variants and is expected to be